A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies
Crossref DOI link: https://doi.org/10.1136/jclinpath-2018-205362
Published Online: 2018-10-01
Published Print: 2018-12
Update policy: https://doi.org/10.1136/crossmarkpolicy
Batenchuk, Cory
Albitar, Maher
Zerba, Kim
Sudarsanam, Sucha
Chizhevsky, Vladislav
Jin, Chelsea
Burns, Virginia
Funding for this research was provided by:
Bristol-Myers Squibb (This study was supported by Bristol-Myers Squibb)